{"id":71840,"date":"2026-08-06T14:43:08","date_gmt":"2026-08-06T06:43:08","guid":{"rendered":"https:\/\/flcube.com\/?p=71840"},"modified":"2026-08-06T14:43:09","modified_gmt":"2026-08-06T06:43:09","slug":"remegen-forecasts-h1-2026-revenue-of-rmb-5-85b-net-profit-of-rmb-4-70b-on-telitacicept-and-abbvie-licensing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71840","title":{"rendered":"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>RemeGen Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688331:SHA\">SHA: 688331<\/a>, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9995:HKG\">HKG: 9995<\/a>) released its <strong>performance forecast for the first half of 2026<\/strong>, expecting <strong>total revenue of approximately RMB 5.85 billion<\/strong>, representing a <strong>433% year-over-year increase<\/strong> (up RMB 4.752 billion from H1 2025). The company also forecasts <strong>net profit attributable to shareholders of approximately RMB 4.70 billion<\/strong> and <strong>adjusted net profit of RMB 4.30 billion<\/strong>, marking a dramatic turnaround from losses in the same period last year.<\/p>\n\n\n\n<h2 id=\"h-financial-forecast-summary-h1-2026\" class=\"wp-block-heading\">Financial Forecast Summary | H1 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1 2026 Forecast<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 5.85 billion<\/td><td>+433% (+RMB 4.752B)<\/td><\/tr><tr><td><strong>Net Profit (GAAP)<\/strong><\/td><td>RMB 4.70 billion<\/td><td>Turnaround from loss<\/td><\/tr><tr><td><strong>Adjusted Net Profit<\/strong><\/td><td>RMB 4.30 billion<\/td><td>Turnaround from loss<\/td><\/tr><tr><td><strong>Profit Margin<\/strong><\/td><td>~80% (GAAP)<\/td><td>Significant improvement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-revenue-drivers-amp-growth-catalysts\" class=\"wp-block-heading\">Revenue Drivers &amp; Growth Catalysts<\/h2>\n\n\n\n<h3 id=\"h-core-product-commercial-success\" class=\"wp-block-heading\">Core Product Commercial Success<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Telitacicept<\/strong>: Continued strong domestic sales growth of the company&#8217;s flagship lupus treatment<\/li>\n\n\n\n<li><strong>Disitamab Vedotin<\/strong>: Robust performance of the HER2-targeting antibody-drug conjugate in domestic markets<\/li>\n\n\n\n<li><strong>Commercial Execution<\/strong>: Enhanced market penetration and physician adoption driving sustained volume growth<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-licensing-partnership\" class=\"wp-block-heading\">Strategic Licensing Partnership<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AbbVie Agreement<\/strong>: Exclusive license deal for <strong>PD-1\/VEGF bispecific antibody RC148<\/strong><\/li>\n\n\n\n<li><strong>Territory<\/strong>: AbbVie obtained exclusive rights to develop, manufacture, and commercialize RC148 <strong>outside Greater China<\/strong><\/li>\n\n\n\n<li><strong>Revenue Impact<\/strong>: Significant upfront and milestone payments contributing to H1 2026 revenue surge<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: Validates RemeGen&#8217;s bispecific antibody platform and provides non-dilutive funding for pipeline advancement<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-operational-transformation\" class=\"wp-block-heading\">Operational Transformation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Profitability Turnaround<\/strong>: Transition from H1 2025 losses to substantial H1 2026 profits demonstrates successful commercial scaling<\/li>\n\n\n\n<li><strong>Operating Leverage<\/strong>: High profit margins reflect efficient cost structure and strong pricing power for innovative biologics<\/li>\n\n\n\n<li><strong>Cash Generation<\/strong>: Robust profitability provides financial flexibility for pipeline investment and strategic initiatives<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-remegen\" class=\"wp-block-heading\">For RemeGen<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Strong commercial performance validates RemeGen&#8217;s proprietary antibody and bispecific platforms<\/li>\n\n\n\n<li><strong>Financial Strength<\/strong>: Substantial cash generation reduces need for equity financing and enhances strategic optionality<\/li>\n\n\n\n<li><strong>Pipeline Funding<\/strong>: Internal cash flow can support advancement of next-generation candidates without external dilution<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-chinese-biotech-sector\" class=\"wp-block-heading\">For Chinese Biotech Sector<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Premium<\/strong>: Demonstrates that truly differentiated Chinese biotech innovations can command premium valuations and generate substantial profits<\/li>\n\n\n\n<li><strong>Global Partnerships<\/strong>: AbbVie deal highlights international recognition of Chinese biotech innovation quality<\/li>\n\n\n\n<li><strong>Commercial Maturity<\/strong>: Represents evolution from clinical-stage companies to commercially successful enterprises<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The exceptional H1 2026 performance positions RemeGen as one of China&#8217;s most successful commercial-stage biotechnology companies, with a proven ability to translate innovative science into substantial shareholder value.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance and business outlook. Actual results may differ materially due to regulatory developments, competitive dynamics, market adoption rates, and partnership execution risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,1155,375,1294],"class_list":["post-71840","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-hkg-9995","tag-remegen","tag-sha-688331"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half of 2026, expecting total revenue of approximately RMB 5.85 billion, representing a 433% year-over-year increase (up RMB 4.752 billion from H1 2025). The company also forecasts net profit attributable to shareholders of approximately RMB 4.70 billion and adjusted net profit of RMB 4.30 billion, marking a dramatic turnaround from losses in the same period last year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71840\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half of 2026, expecting total revenue of approximately RMB 5.85 billion, representing a 433% year-over-year increase (up RMB 4.752 billion from H1 2025). The company also forecasts net profit attributable to shareholders of approximately RMB 4.70 billion and adjusted net profit of RMB 4.30 billion, marking a dramatic turnaround from losses in the same period last year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71840\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-06T06:43:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-06T06:43:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71840#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71840\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal\",\"datePublished\":\"2026-08-06T06:43:08+00:00\",\"dateModified\":\"2026-08-06T06:43:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71840\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"HKG: 9995\",\"RemeGen\",\"SHA: 688331\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71840#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71840\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71840\",\"name\":\"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-06T06:43:08+00:00\",\"dateModified\":\"2026-08-06T06:43:09+00:00\",\"description\":\"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half of 2026, expecting total revenue of approximately RMB 5.85 billion, representing a 433% year-over-year increase (up RMB 4.752 billion from H1 2025). The company also forecasts net profit attributable to shareholders of approximately RMB 4.70 billion and adjusted net profit of RMB 4.30 billion, marking a dramatic turnaround from losses in the same period last year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71840#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71840\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71840#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half of 2026, expecting total revenue of approximately RMB 5.85 billion, representing a 433% year-over-year increase (up RMB 4.752 billion from H1 2025). The company also forecasts net profit attributable to shareholders of approximately RMB 4.70 billion and adjusted net profit of RMB 4.30 billion, marking a dramatic turnaround from losses in the same period last year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71840","og_locale":"en_US","og_type":"article","og_title":"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal","og_description":"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half of 2026, expecting total revenue of approximately RMB 5.85 billion, representing a 433% year-over-year increase (up RMB 4.752 billion from H1 2025). The company also forecasts net profit attributable to shareholders of approximately RMB 4.70 billion and adjusted net profit of RMB 4.30 billion, marking a dramatic turnaround from losses in the same period last year.","og_url":"https:\/\/flcube.com\/?p=71840","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-06T06:43:08+00:00","article_modified_time":"2026-08-06T06:43:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71840#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71840"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal","datePublished":"2026-08-06T06:43:08+00:00","dateModified":"2026-08-06T06:43:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71840"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","HKG: 9995","RemeGen","SHA: 688331"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71840#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71840","url":"https:\/\/flcube.com\/?p=71840","name":"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-06T06:43:08+00:00","dateModified":"2026-08-06T06:43:09+00:00","description":"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half of 2026, expecting total revenue of approximately RMB 5.85 billion, representing a 433% year-over-year increase (up RMB 4.752 billion from H1 2025). The company also forecasts net profit attributable to shareholders of approximately RMB 4.70 billion and adjusted net profit of RMB 4.30 billion, marking a dramatic turnaround from losses in the same period last year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71840#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71840"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71840#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71840"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71840\/revisions"}],"predecessor-version":[{"id":71841,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71840\/revisions\/71841"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}